Quick Answer
GALECTIN THERAPEUTICS INC reported Operating Income of -$20.09 million for fiscal year 2025.
GALECTIN THERAPEUTICS INC Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$20.09M | +52.7% |
| 2024 | -$42.43M | -11.5% |
| 2023 | -$38.07M | +0.7% |
| 2022 | -$38.35M | -27.1% |
| 2021 | -$30.18M | -28.7% |
| 2020 | -$23.44M | -74.5% |
| 2019 | -$13.44M | +1.2% |
| 2018 | -$13.60M | +16.3% |
| 2017 | -$16.25M | +24.4% |
| 2016 | -$21.48M | -7.0% |
| 2015 | -$20.08M | -30.1% |
| 2014 | -$15.43M | -27.5% |
| 2013 | -$12.10M | -22.3% |
| 2012 | -$9.90M | +4.9% |
| 2011 | -$10.41M | -113.2% |
| 2010 | -$4.88M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.20M | +53.7% | +9.2% |
| June 30, 2025 | -$4.62M | +59.0% | +41.4% |
| March 31, 2025 | -$7.90M | +18.1% | +12.9% |
| September 30, 2024 | -$9.07M | +1.1% | +19.7% |
| June 30, 2024 | -$11.29M | -25.4% | -17.0% |
| March 31, 2024 | -$9.65M | +6.7% | -5.3% |
| September 30, 2023 | -$9.17M | -12.9% | -1.8% |
| June 30, 2023 | -$9.00M | +6.8% | +12.9% |
- GALECTIN THERAPEUTICS INC showed an increase of +52.7% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, GALECTIN THERAPEUTICS INC’s operating income has declined by 311.3% (from -$4.88 million to -$20.09 million).
- The most recent figure is from GALECTIN THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: